Active, Not Recruiting
An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread - CA030-001
Oppdatert: 3 oktober, 2023 | ClinicalTrials.gov
Fase
Kjønn
Aldersgruppe
Active, Not Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Participants must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies Exclusion Criteria: - Participants with primary CNS malignancies or tumors with CNS metastases as the only site of disease, will be excluded - Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted - Participants with other active malignancy requiring concurrent intervention Other protocol defined inclusion/exclusion criteria could apply
Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon
MLTNO2000046
